Urology News and Research

Latest Urology News and Research

Nocturia affects one in three premenopausal women

Nocturia affects around one-third of women of reproductive age, a survey has found, highlighting that the condition is not confined to elderly individuals.

15 Jul 2014

New research explores why active surveillance underused in patients with prostate cancer

New research from The University of Texas MD Anderson Cancer Center is shedding light on the important role a diagnosing urologist plays in whether older men with low-risk prostate cancer receive treatment for their disease, and if so, the type of treatment they receive as a result.

15 Jul 2014

UH Case Medical Center named one of nation's top hospitals

University Hospitals Case Medical Center has once again been named one of the nation's top hospitals, according to U.S. News & World Report's annual Best Hospitals rankings. UH Case Medical Center was ranked in all 12 methodology-ranked specialties for the third year in a row and in the Top 20 in four specialties - Cancer, Gastroenterology, Ear, Nose & Throat, and Orthopaedics.

15 Jul 2014

NAFC updates Male Stress Urinary Incontinence content

The National Association For Continence (NAFC) has updated the Male Stress Urinary Incontinence content at www.nafc.org. The new content is designed to be more patient friendly and includes an educational video, as well as additional resources about the diagnosis, treatment, and management of Male Stress Urinary Incontinence.

11 Jul 2014

Study examines whether men who ride have higher risk of erectile dysfunction, infertility, prostate cancer

Cycling is a popular activity that offers clear health benefits, but there is an ongoing controversy about whether men who ride have a higher risk of urogenital disorders such as erectile dysfunction, infertility, or prostate cancer.

8 Jul 2014

Protein may predict outcome of targeted mccRCC therapy

Levels of carbonic anhydrase 9 increase with the use of vascular endothelial growth factor-targeted therapy for metastatic clear-cell renal cancer, and high expression of this protein is associated with increased survival, show study results reported in European Urology.

3 Jul 2014

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

2 Jul 2014

LUTS highly prevalent in western Turkish population

Researchers have published the first-ever estimate of the prevalence of lower urinary tract symptoms, overactive bladder and urinary incontinence in the population of western Turkey.

30 Jun 2014

Metabolic syndrome components may influence LUTS/BPH

Abdominal aortic calcification and visceral fat obesity each seem to influence lower urinary tract symptoms in men with benign prostatic hyperplasia, study findings suggest.

30 Jun 2014

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.

30 Jun 2014

FDA grants Thermedx 510(k) clearance for optional fluid warming in arthroscopic, hysteroscopic procedures

Thermedx, LLC, an innovative designer and manufacturer of "smart" surgical irrigation products, received FDA 510(k) clearance for optional fluid warming in arthroscopic and hysteroscopic procedures.

30 Jun 2014

Chesapeake Urology presents $114,248 to Urology Care Foundation for prostate cancer research

In ongoing support of prostate cancer research, Sanford Siegel, M.D., President and CEO of Chesapeake Urology Associates, presented the Urology Care Foundation with a check for $114,248 in support of its prostate cancer research efforts.

28 Jun 2014

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

Ferring Pharmaceuticals, Roche partner to make personalised infertility treatment possible

Ferring Pharmaceuticals and Roche have announced a collaboration to combine diagnostic testing technology from Roche with Ferring's human cell line derived recombinant follicle-stimulating hormone (human rFSH), a gonadotrophin currently in phase III development.

24 Jun 2014

OAB and interstitial cystitis/bladder pain syndrome show considerable overlap

There is considerable overlap between symptoms in patients with interstitial cystitis/bladder pain syndrome and those with overactive bladder, US researchers have shown.

23 Jun 2014

LABORIE completes acquisition of BUCK Elektromedizin and BUCKmeditec

Laborie Medical Technologies, Inc., based in Toronto, Ontario, has completed its acquisition of BUCK Elektromedizin GmbH and BUCKmeditec GmbH & Co. Bad Rappenaeau, Germany based BUCK develops and distributes innovative and advanced biofeedback and electrical stimulation equipment, accessories and consumables for pelvic floor dysfunction in the treatment of urinary and fecal incontinence.

18 Jun 2014